Crinetics Pharmaceuticals (CRNX) Retained Earnings (2017 - 2026)

Crinetics Pharmaceuticals' Retained Earnings history runs 10 years deep, the most recent figure standing at -$1.5 billion for Q1 2026.

• In Q1 2026, Retained Earnings fell 77286.41% year-over-year to -$1.5 billion; the TTM figure through Mar 2026 stood at -$1.5 billion (down 77286.41% YoY), while the FY2025 annual figure was -$1.4 billion, down 48.87% from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.5 billion, down from -$1.4 billion in the prior quarter.
• The five-year high for Retained Earnings was $2.0 million in Q1 2025, with the low at -$1.5 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$2.5 million (2023), against an average of -$427.6 million.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings plunged 3523100.0% in 2022, then surged 1234.67% in 2025.
• Crinetics Pharmaceuticals' Retained Earnings stood at -$439.2 million in 2022, then jumped by 100.22% to $977000.0 in 2023, then sank by 97552.41% to -$952.1 million in 2024, then slumped by 48.87% to -$1.4 billion in 2025, then dropped by 9.02% to -$1.5 billion in 2026.
• Business Quant data shows CRNX's Retained Earnings at -$1.5 billion in Q1 2026, -$1.4 billion in Q4 2025, and -$1.3 billion in Q3 2025.